Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 1, 2025
Identifying locally recurrent versus second primary breast cancer: Genomic versus clinical criteria from Carolina Breast Cancer Study Phase IIISarah C Van Alsten, Michael I Love, Benjamin C Calhoun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsPatrick J Roberts, Jerry E Usary, David B Darr, et al.
Cancer Cell|June 16, 2012
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanomaWenjin Liu, Kimberly B Monahan, Adam D Pfefferle, et al.
Scientific Reports|December 9, 2022
Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancerNarmeen S Rashid, David C Boyd, Amy L Olex, et al.
Biorxiv : the Preprint Server for Biology|March 16, 2026
Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancersMatthew D Sutcliffe, Kevin R Mott, Tulay Yilmaz-Swenson, et al.
NPJ Breast Cancer|March 6, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapyTomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, et al.
Gynecologic Oncology|March 8, 2025
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG studyVictoria L Bae-Jump, Michael W Sill, Paola A Gehrig, et al.
Nature Communications|February 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.
JCO Precision Oncology|July 9, 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL TrialYash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, et al.
Pageof 3